Germany's Magna Diagnostics Heading Development of Point-of-Care Molecular Testing Platform
January 06, 2011
Germany's Magna Diagnostics Heading Development of Point-of-Care Molecular Testing Platform
Magna is spearheading a public-private consortium to develop a point-of-care molecular testing platform based on magnetic nanoparticles and PCR amplification. Other partners in the consortium include the Fraunhofer Institute and Siemens.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Lumora-FIND Malaria Screening Test May be Tip of Iceberg in MDx Development Partnership
April 18, 2013 / PCR Insider - SIRS-Lab Commences Clinical Trial for PCR-Array-Based Sepsis Test
March 24, 2011 / PCR Insider - Analytik Jena Buys Assets of Insolvent MDx Firm SIRS-Lab
May 6, 2013 / GenomeWeb Daily News - BioFire Nabs Additional $20M Investment
May 2, 2013 / GenomeWeb Daily News - BioFire Files 510(k) Submission to FDA for Blood Culture Panel
April 16, 2013 / GenomeWeb Daily News